Management of Refractory Thrombosis in Cancer Patients
Introduction to Anticoagulation Therapy
- For patients with refractory thrombosis and cancer, the American Society of Hematology recommends increasing the dose of low molecular weight heparin (LMWH) by 25% of the current dose or up to weight-adjusted therapeutic doses if they were receiving non-therapeutic doses 1
- The International Society on Thrombosis and Haemostasis suggests confirming adherence to anticoagulant treatment, ruling out heparin-induced thrombocytopenia (HIT), and verifying the type of current anticoagulant 1
Adjusting Anticoagulation Therapy
- If the patient is receiving vitamin K antagonists (VKAs), the American College of Chest Physicians recommends switching to LMWH at weight-adjusted therapeutic doses 1
- If the patient is already receiving LMWH, the guideline suggests increasing the LMWH dose by approximately 25% or up to the weight-adjusted therapeutic dose if they were receiving non-therapeutic doses 1
- The European Society of Medical Oncology recommends reevaluating the patient 5-7 days after the dose increase and considering another dose increase if there is no symptomatic improvement 1
Laboratory Monitoring
- For adjusting the dose, the International Society on Thrombosis and Haemostasis suggests using anti-FXa levels:
Alternative Anticoagulants
- The American Society of Clinical Oncology states that fondaparinux and VKAs are associated with a higher risk of recurrent thrombosis than LMWH in cancer patients 1
- The guideline recommends against using inferior vena cava filters as they do not provide a net benefit in preventing recurrent thrombosis and have no impact on survival 1, 2
Specific Anticoagulant Regimens
- Dalteparin: 200 UI/kg subcutaneously once daily for the first month, then 150 UI/kg subcutaneously once daily for months 2-6 3
- Enoxaparin: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily 3
- Tinzaparina: 175 U/kg subcutaneously once daily 3
Special Considerations
- The American Society of Hematology recommends individualized anticoagulation in patients with thrombocytopenia after evaluating risks and benefits 1
- The guideline suggests that patients with cancer and recurrent thromboembolic events have a short median survival, making effective management crucial 1